Come up with a name for your new list and we'll add to it:
ContraFect raised a round of funding on September 15, 2011. Investors include
Equity Source Partners.
ContraFect is a biotechnology company committed to developing technologies, treatments, and products that will target and kill the most virulent and resistant microorganisms-including gram-positive ba…